Renalytix, partners awarded $10M Horizon Europe grant

Renalytix announces the launch of PRIME-CKD, a consortium of industry, academic and clinical research leaders, that aims to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with chronic kidney disease, CKD. PRIME-CKD is funded by Horizon Europe, the European Union’s key funding program for research and innovation. The total budget of the project is $10M over a projected five-year period with approximately 10% of the budget targeted for commercial translation activities to be undertaken by Renalytix. "We expect the project to benefit from Renalytix’s substantial expertise in biomarker research translation and existing intellectual property on urinary Epidermal Growth Factor for which Renalytix has exclusive access from the University of Michigan," the company said. The consortium brings together leading experts from 11 academic institutions, together with partners from patient representative foundations and regulatory agencies. Fergus Fleming, Chief Technology Officer of Renalytix who will serve on the steering committee for PRIME-CKD and lead the implementation of the research outputs into clinical practice, added: "The opportunity to participate in the PRIME-CKD program combined with ongoing development of novel biomarkers from our collaboration with Joslin Diabetes Center and planned data generation in completed clinical studies expected in 2023, further strengthens KidneyIntelX as a precision medicine platform in CKD."